Co-Diagnostics Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Co-Diagnostics stock.
View analyst ratings for Co-Diagnostics or view top-rated stocks.

Wall Street analysts have given Co-Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Co-Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for Co-Diagnostics.

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its earnings results on Sunday, November, 15th. The company reported $0.53 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.63 by $0.10. The business earned $21.82 million during the quarter, compared to analysts' expectations of $28 million. Co-Diagnostics had a trailing twelve-month return on equity of 93.48% and a net margin of 53.81%.
View Co-Diagnostics' earnings history.

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CODX stock has increased by 4.8% and is now trading at $13.82.
View which stocks have been most impacted by COVID-19.

Co-Diagnostics issued an update on its fourth quarter 2020 IntraDay earnings guidance on Wednesday, January, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $26.184-27.275 million, compared to the consensus revenue estimate of $24.99 million.

2 analysts have issued 12 month target prices for Co-Diagnostics' shares. Their forecasts range from $20.00 to $30.00. On average, they anticipate Co-Diagnostics' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 80.9% from the stock's current price.
View analysts' price targets for Co-Diagnostics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Co-Diagnostics include Luminex (LMNX), GenMark Diagnostics (GNMK), Alphatec (ATEC), MiMedx Group (MDXG), Atrion (ATRI), Cerus (CERS), LeMaitre Vascular (LMAT), SI-BONE (SIBN), CryoLife (CRY), OrthoPediatrics (KIDS), Tactile Systems Technology (TCMD), Orthofix Medical (OFIX), AngioDynamics (ANGO), OraSure Technologies (OSUR) and Intersect ENT (XENT).
View all of CODX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.80%), Nuveen Asset Management LLC (2.45%), Northern Trust Corp (1.08%), Bank Julius Baer & Co. Ltd Zurich (0.61%), Principal Financial Group Inc. (0.53%) and Bank of New York Mellon Corp (0.53%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics.

CODX stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Schroder Investment Management Group, IFG Advisory LLC, ExodusPoint Capital Management LP, Creative Planning, JPMorgan Chase & Co., Barclays PLC, and ETF Managers Group LLC. Company insiders that have sold Co-Diagnostics company stock in the last year include Dwight H Egan, Eugene Durenard, Reed L Benson, and Richard S Serbin.
View insider buying and selling activity for Co-Diagnostics or view top insider-selling stocks.

CODX stock was purchased by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., Bank Julius Baer & Co. Ltd Zurich, BlackRock Inc., Price T Rowe Associates Inc. MD, Bank of New York Mellon Corp, Nuveen Asset Management LLC, Summit Wealth & Retirement Planning Inc., and Panagora Asset Management Inc..
View insider buying and selling activity for Co-Diagnostics or or view top insider-buying stocks.

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CODX stock can currently be purchased for approximately $13.82.

Co-Diagnostics has a market capitalization of $390.68 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

Co-Diagnostics employs 39 workers across the globe.

The official website for Co-Diagnostics is www.codiagnostics.com.

Co-Diagnostics is headquartered at 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124.

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected]